Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Rhea-AI Summary

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT. Investors can access a live webcast of the presentation through the Company's website. A replay will be available for two weeks following the event. Concert is a late-stage clinical biopharmaceutical company known for developing deuruxolitinib (CTP-543), an oral JAK1/2 inhibitor for alopecia areata. The company is exploring other indications and has multiple pipeline candidates.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

A webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005071/en/

Justine Koenigsberg

(781) 674-5284

ir@concertpharma.com

Source: Concert Pharmaceuticals

FAQ

When is Concert Pharmaceuticals participating in the Jefferies London Healthcare Conference?

Concert Pharmaceuticals will participate in the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

Where can I watch the Concert Pharmaceuticals presentation?

The presentation can be accessed via webcast on Concert Pharmaceuticals' website in the Investors section.

What is deuruxolitinib, developed by Concert Pharmaceuticals?

Deuruxolitinib (CTP-543) is an oral JAK1/2 inhibitor developed for treating alopecia areata and is in late-stage clinical trials.

How long will the replay of the Concert Pharmaceuticals presentation be available?

A replay of the presentation will be available on Concert Pharmaceuticals' website for two weeks after the event.

What is the focus of Concert Pharmaceuticals?

Concert Pharmaceuticals focuses on developing innovative treatments, including deuruxolitinib and other pipeline candidates.